-
Recombinant EGFR protein (672-1210, L858R) protein
Recombinant EGFR protein (672-1210, L858R) protein
- 中文名称：
- Recombinant EGFR protein (672-1210, L858R) protein
- 英文名称：
- Recombinant EGFR protein (672-1210, L858R) protein
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA60175
- 规格：
- 0.02 mg|2x0.02 mg|3x0.02 mg|4x0.02 mg|5x0.02 mg
- 保存建议：
- Recombinant proteins in solution are temperature sensitive and must be stored at -80 degree C to prevent degradation. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Shipping Temp: Dry Ice
- 货期：
- 6-8周
- CAS号：
- 601-75-2
- 纯度：
- N/A
- 产品形式：
- Recombinant EGFR (672-1210, L858R) protein is supplied in 25mM HEPES-NaOH pH7.5, 300mM NaCl, 10% glycerol, 0.04% Triton X-100, and 0.5mM TCEP.
- 分子量：
- 132.11 g/mol
- 分子式：
- C5H8O4
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Short Description: Recombinant human EGFR (672-1210, L858R) protein includes amino acids 672-1210 of human EGFR protein (accession number NP_005219.2) with a point mutation Leu858Arg; it was expressed in a baculovirus expression system with an N-terminal DYKDDDDK-Tag. The molecular weight of this protein is 63.1 kDa. Recombinant human EGFR (672-1210, L858R) protein is suitable for use in the study of enzyme kinetics, inhibitor screening, and selectivity profiling.
Background: EGFR (Epidermal Growth Factor Receptor), also known as ERBB, mENA, ERBB1 and HER1, is the receptor for members of the EGF family and is a transmembrane glycoprotein that has tyrosine kinase activity. Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homoand/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades, including at least 4 major downstream signaling cascades: the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules, leading to cell proliferation. EGFR is widely recognized for its importance in cancer. Amplification and mutations of this gene have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. In particular, EGFR mutation analysis of NSCLC (non-small cell lung cancer) is now routine in standard clinical practice, and tyrosine kinase inhibitors (TKIs) targeting EGFR-activating mutations are the most widely used targeted therapy, most notably gefitinib and erlotinib. Patients carrying a point mutation in exon 21 (L858R) or a deletion in exon 19, which account for approximately 90% of EGFR-activating mutations, have significant survival benefit when treated with EGFR-TKI.
